论文部分内容阅读
有关塘尿病(DM)病理学研究,目前已进入基因水平,其成果正在逐渐具体地反映在临床上。相反,尚无线索可寻的问题也堆积如山。本文仅就糖尿病的诊断与治疗方面最近几个专题加以讨论。一、糖基化血红蛋白(glycosylated hemoglob-in)蛋白质的糖化率是与某个时期的血糖平均水平平行,如测定寿命明确的蛋白质糖化率就能大致了解过去一定时期血糖平均水平。从这种意义上说,测定寿命为120天的血红蛋白糖化率作为推测过去1～2个月的血糖控制情况的指标,这在临床上非常有用。测定糖基化白蛋白(半衰期17天)用来推测过去数周里的血糖控制情况,进而对判定以临床上发作(如脑血
The pathological study of the disease of the kidney (DM) has now entered the genetic level and its results are gradually and specifically reflected in clinical practice. On the contrary, there are no questions yet to be found on the trail. This article discusses only the most recent topics on the diagnosis and treatment of diabetes. First, the glycosylated hemoglobin (glycosylated hemoglob-in) protein saccharification rate with the average level of blood glucose during a period of parallel, such as measuring the life expectancy of the protein saccharification rate can be roughly the past a certain period of average blood glucose level. In this sense, measuring the hemoglobin saccharification rate for 120 days as a measure of the glycemic control over the past 1 to 2 months is very clinically useful. Determination of glycosylated albumin (half-life of 17 days) is used to speculate over the past few weeks of glycemic control, and then determine the clinical onset (such as cerebral blood